SEC Tracker
Get the app

Macrogenics MGNX

Macrogenics reports stock option and RSU grant to Michael Vasconcelles

Michael Vasconcelles (Director) reported option or other derivative trades in MGNX

Form
4
Filed
Importance
Routine
  1. Stock option for 44,000 shares at $2.4
  2. Restricted stock units (shares paid out over time) for 7,500 shares
  3. Options vest over 36 months starting November 2026

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Macrogenics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Inovio Pharmaceuticals INO public float $74M, Jun 30, 2025
  2. Volitionrx VNRX public float $73M, Jun 30, 2025
  3. Gyre Therapeutics GYRE public float $73M, Jun 30, 2025
  4. Oncolytics Biotech ONCY public float $72M, Jun 30, 2025
  5. Seres Therapeutics MCRB public float $72M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.